Feb 5, 2004
Britain's biggest biotech firm Celltech said on Thursday it had entered into a collaboration to research, develop and commercialise treatments for autoimmune diseases with U.S. peer Biogen Idec.
Celltech said it would be responsible for identifying and engineering new antibodies to treat diseases such as rheumatoid arthritis and multiple sclerosis, and will pay all development costs until the end of Phase I clinical trials.
Biogen Idec will then have the option to co-invest in the ongoing development
of the products.
Copyright © 2004, Reuters